Loading clinical trials...
Loading clinical trials...
Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \[18F\]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of \[18F\]GATT-44 by performing whole-body imaging studies.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
Yes
Yale University PET Center
New Haven, Connecticut, United States
Start Date
March 1, 2026
Primary Completion Date
January 1, 2030
Completion Date
January 1, 2030
Last Updated
March 9, 2026
32
ESTIMATED participants
[ 18F]GATT-44
DRUG
Lead Sponsor
Yale University
Collaborators
NCT07483606
NCT06342713
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions